New antibody combo offers hope for hard-to-treat multiple myeloma
NCT ID NCT07210047
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 29 times
Summary
This study tests whether a new antibody drug called HuL001, combined with two standard drugs (lenalidomide and dexamethasone), is safe and works for people with multiple myeloma that has come back or stopped responding to prior treatments. About 21 adults will receive HuL001 injections every two weeks plus daily lenalidomide and weekly dexamethasone. The goal is to control the disease, not cure it, as ongoing treatment is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Far Eastern Memorial Hospital
Taipei, Taiwan
Conditions
Explore the condition pages connected to this study.